Skip to content


Rinvoq (upadacitinib) is a small molecule pharmaceutical. Upadacitinib was first approved as Rinvoq on 2019-08-16. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, tyrosine-protein kinase JAK2, and non-receptor tyrosine-protein kinase TYK2. Rinvoq's patents are valid until 2036-10-17 (FDA).
Trade Name Rinvoq
Common Name Upadacitinib
Indication rheumatoid arthritis
Drug Class Tyrosine kinase inhibitors: janus kinase inhibitors
Get full access now